ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
65,938.74
1.16%
S&P 500
5,748.05
0.05%
Dow Jones
42,402.58
0.54%
US Dollar vs Yen
142.3405
-1.91%
Brent Oil
71.065
0.16%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Capricor Therapeutics Inc (CAPR)

  7. Capricor Therapeutics Inc (CAPR) ニュース

CAPR

Capricor Therapeutics (CAPR)

Capricor Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:CAPR
日付受信時刻ニュースソース見出しコード企業名
2024/09/2505 : 03Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:CAPRCapricor Therapeutics Inc
2024/09/2505 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CAPRCapricor Therapeutics Inc
2024/09/2505 : 01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CAPRCapricor Therapeutics Inc
2024/09/2421 : 00GlobeNewswire Inc.Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy CardiomyopathyNASDAQ:CAPRCapricor Therapeutics Inc
2024/09/2322 : 25GlobeNewswire Inc.Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024NASDAQ:CAPRCapricor Therapeutics Inc
2024/09/1722 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CAPRCapricor Therapeutics Inc
2024/09/1722 : 15GlobeNewswire Inc.Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
2024/09/0621 : 30GlobeNewswire Inc.Capricor Therapeutics to Present at Upcoming Investor and Scientific ConferencesNASDAQ:CAPRCapricor Therapeutics Inc
2024/08/2405 : 02Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CAPRCapricor Therapeutics Inc
2024/08/2405 : 01Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:CAPRCapricor Therapeutics Inc
2024/08/0922 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CAPRCapricor Therapeutics Inc
2024/08/0906 : 00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CAPRCapricor Therapeutics Inc
2024/08/0805 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CAPRCapricor Therapeutics Inc
2024/08/0805 : 05GlobeNewswire Inc.Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CAPRCapricor Therapeutics Inc
2024/07/3122 : 00GlobeNewswire Inc.Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7NASDAQ:CAPRCapricor Therapeutics Inc
2024/07/0122 : 00GlobeNewswire Inc.Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® IndexesNASDAQ:CAPRCapricor Therapeutics Inc
2024/06/2822 : 00GlobeNewswire Inc.Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
2024/06/2523 : 30GlobeNewswire Inc.CORRECTION: Capricor TherapeuticsNASDAQ:CAPRCapricor Therapeutics Inc
2024/06/2521 : 30GlobeNewswire Inc.Capricor Therapeutics Announces for the Treatment of Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
2024/06/1505 : 31Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CAPRCapricor Therapeutics Inc
2024/06/1122 : 25GlobeNewswire Inc.Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA PathwayNASDAQ:CAPRCapricor Therapeutics Inc
2024/06/0422 : 00GlobeNewswire Inc.Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
2024/05/1606 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CAPRCapricor Therapeutics Inc
2024/05/1606 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CAPRCapricor Therapeutics Inc
2024/05/1422 : 00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CAPRCapricor Therapeutics Inc
2024/05/1405 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CAPRCapricor Therapeutics Inc
2024/05/1405 : 05GlobeNewswire Inc.Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CAPRCapricor Therapeutics Inc
2024/05/0922 : 15GlobeNewswire Inc.Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingNASDAQ:CAPRCapricor Therapeutics Inc
2024/05/0822 : 00GlobeNewswire Inc.Capricor Therapeutics to Present at Upcoming Scientific and Medical ConferencesNASDAQ:CAPRCapricor Therapeutics Inc
2024/05/0622 : 00GlobeNewswire Inc.Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13NASDAQ:CAPRCapricor Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CAPR

最近閲覧した銘柄

NASDAQ
ITLA
Itla Capital
NASDAQ
ABBAEXX
Hsbc Usa Inc Autocallabl...
BIT
ECMD
Inv Eur Corp Shrtdur Mf ...
USOTC
OERLF
Oc Oerlikon (PK)
LSE
3NVD
Ls 3x Nvidia
BIT
F09391
Vontobel Financial Produ...
AMEX
OTD
O2 Diesel
COIN
WINWEUR
LSE
FB52
Citi Fun 29
COIN
QBITUSD
USOTC
FRRFF
4imprint (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有